Other
Patient Preference
0
Pipeline Programs↗
3
Active Trials↗
6
Companies Involved↗
Patient Preference is an early-stage landscape with 0 programs across 6 companies. The most active players are GSK, Novartis, Bayer.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
21
clinical trials
Completed17 · 81%
Recruiting3 · 14%
Withdrawn1 · 5%
Clinical Trials
Trial Activity
21 trials
Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
Recruiting·—·Phase 2·NCT07223424·480 enrolled
Patient Preferences on Same-day Bilateral Intravitreal Dexamethasone Injections
Recruiting·—·N/A·NCT06894017·200 enrolled
Single Dose Crossover Study of Patient Preference for Unscented Nasonex® Nasal Spray Versus Scented Flonase® Nasal Spray (Study P04207)
Completed·—·Phase 4·NCT00817050·100 enrolled
Study of Patient Preference for Oral or Intravenous Vinorelbine in the Treatment of Advanced NSCLC
Completed·IIstituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS·Phase 4·NCT01848613·120 enrolled
Single Dose Crossover Study of Patient Preference for Unscented Nasonex® Nasal Spray Versus Scented Flonase® Nasal Spray (Study P04208)
Completed·—·Phase 4·NCT00783458·100 enrolled
Safety, Efficacy, and Patient Preference of Split-Dose Crystalline Lactulose as a Preparation for Colonoscopy in Adults
Completed·—·Phase 2·NCT01650870·40 enrolled
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)